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M ucormycosis is an uncommon acute and often 
fatal opportunistic fungal infection that usually 
occurs in patients with poorly controlled diabetes mel- 
litus, acute leukemias, or other immunosuppressive 
conditions [1,2]. A new association, that  of mucormy- 
cosis occurring in patients receiving deferoxamine 
therapy for iron or aluminum excess, has been report- 
ed with increasing frequency since 1986 [3-16]. Al- 
though this association has been strongly linked with 
chronic renal failure requiring hemodialysis, it is now 
clear that other conditions in which deferoxamine may 
be required (thalassemia, sideroblastic anemia, myelo- 
dysplasia) are also associated with mucormycosis 
[5,7,8,16]. We report a case of mucormycosis in a pa- 
tient who had received deferoxamine for iron overload 
secondary to myelodysplastic syndrome, and review 
previous cases of deferoxamine-associated mucormy- 
cosis. 
CASE REPORT 
A 56-year-old woman with myelodysplastic syn- 
drome for six years and transfusion-related iron over- 
load had received treatment with deferoxamine, 1 to 
1.5 g per week, for seven months. She did well until 
June 1988, when she developed fever and a nonpro- 
ductive cough. She was admitted to another hospital 
where she was treated with tobramycin, ticarcillin- 
clavulanic acid, and erythromycin for presumed pneu- 
monia. Over the course of the first hospital day, she 
remained febrile to 40.0°C and became somnolent and 
disoriented. The next day she was transferred to the 
University of Michigan Medical Center. 
Upon arrival, her temperature was 40.1°C, pulse 100 
beats/minute, and blood pressure 140/78 mm Hg. She 
was lethargic, but arousable, and oriented to place and 
person. Although she had a right gaze preference, her 
eyes were able to cross the midline. A dense left visual 
field deficit was present; no papilledema was present. 
0ropharyngeal examination revealed only multiple 
palatal petechiae. Auscultation of the lungs detected 
scattered rhonchi. Her abdomen was soft and diffusely 
tender, and the splenic tip was palpable. Deep tendon 
reflexes were normal with bilateral flexor plantar re- 
sponses. 
Results of laboratory tests showed a white blood cell 
count of 16,000/#L with six neutrophils, eight band 
forms, 25 lymphocytes, 58 monocytes, one eosinophil, 
one basophil, and one metamyelocyte; hematocrit  of 
24%; and platelet count of 82,000/pL. Serum glucose 
was 102 mg/dL, creatinine was 1.2 mg/dL, and electro- 
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lyte levels were normal. The chest roentgenogram 
showed a 6-cm left perihilar mass. Head computed 
tomographic scan revealed a 3 × 4-cm non-enhancing 
low-attenuation right posterior parietal lesion that  
obliterated several sulci. She was treated with imi- 
penem-cilastatin, acyclovir, and dexamethasone. 
Over the next 18 hours, the patient showed neuro- 
logic deterioration with meningismus and bilateral ex- 
tensor plantar responses. On the third day of hospital- 
ization, amphotericin B was added to the t reatment  
regimen. Bronchoscopy revealed a few yeast and 
Gram-positive diplococci in the washings; no organ- 
isms were found in specimens obtained by transbron- 
chial lung biopsy. Her neurologic condition worsened 
with decreased responsiveness and left hemiplegia. 
The patient underwent intubation and ventilation and 
she was given mannitol. However, the right pupil be- 
came fixed and dilated, she remained febrile to 39.4°C, 
and she died the next day. 
Necropsy revealed central nervous system and pul- 
monary mucormycosis. Cerebral edema and a right 
parieto-occipital infarct were present. Microscopical- 
ly, extensive infiltration of the right cerebral hemi- 
sphere and cerebral vessels by large non-septate hy- 
phae was visible. The left pulmonary artery was 
occluded by a friable mass that  invaded the wall, and 
the adjacent lung showed a large wedge-shaped hem- 
orrhagic infarct. Microscopically, the mass in the pul- 
monary artery was composed of hyphae, multiple pul- 
monary vessels contained fungal emboli, and the lung 
was extensively infiltrated with fungi showing broad 
non-septate hyphae. Cultures of all fungal masses 
yielded Rhizopus species. 
RESULTS 
Although the first dialysis patient with mucormyco- 
sis, reported by Gluskin et al [17], was not noted to be 
receiving deferoxamine, subsequent cases of mucor- 
mycosis in patients undergoing dialysis have been in 
those receiving deferoxamine for aluminum or iron 
excess [6-13,15]. In addition to patients with renal 
failure, patients with hematologic disorders, all of 
whom were treated with deferoxamine, have been re- 
ported with mucormycosis [3-5,14,16]. Including the 
current one, we have found 26 cases of mucormycosis 
associated with states of iron or aluminum excess 
treated with deferoxamine (Table  I). 
Of the cases described in detail, 19 men and seven 
women were affected. The mean age was 49.6 years, 
with a range from 28 to 70 years. Of those cases in 
which the organism was identified, Rhizopus species 
occurred in 13 [6,10,11,15,16] and Cunninghamella 
bertholletiae in three [4,5,t4]. 
Chronic renal disease requiring maintenance hemo- 
dialysis was present in 20 of the 26 patients (77%) [6- 
13,15], whereas the remaining six patients had hema- 
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TABLE I 
Mucormycosls in Patients Receiving Deferoxamine for Iron or Aluminum Excess 
I)eferoxamlno Therapy 
Underlying Dose Duration Organs Treatment/ 
Reference A g e / S e x  Conditions (g/week) (months) Reason Organism Involved Outcome 
[3] 65/M Sideroblastic NS 4 Fe NS Heart, lung, None/died 
anemia brain, kidney, 
spleen, liver, 
adrenal 
[4] 7O/M Thalassemia, NS NS Fe Cunning- Rhinocerebral Surgery/died 
sideroblastic hamella AraB 
anemia, diabetes 
[5] 42/M Thalassemia, NS NS Fe Cunning- 
splenectomy, hamella 
chemotherapy 
[6] 32/M Dialysis 7 0.6 AI Rhizopus 
[7] 32/M Dialysis, 2.5-6 18 AI/Fe NS 
splenectomy 
[8] 45/M Dialysis 2-6 4 AI NS 
57/M Dialysis 4-6 10 Fe NS 
[9] NS/M Dialysis 2-4 4 AI NS 
NS/M Dialysis 2-4 12 AI NS 
[10] 47/F Dialysis, 4 12 AI/Fe Rhizopus 
splenectomy 
36/F Dialysis 4 6 AI Rhizopus 
6O/ i  Dialysis 3 ]2 AI Rhizopus 
45/M Dialysis 3 18 AI Rhizopus 
70/M Dialysis 6 1 AI Rhizopus 
[11] 68/F Dialysis 1.5 12 AI Rhizopus 
36/M Dialysis 4 3 AI Rhizopus 
42/M Dialysis 6 2.5 AI Rhizopus 
49/M Dialysis 6 9 Fe Rhizopus 
[12] 28/F Dialysis 2 5 AI/Fe NS 
[13] 49/M Dialysis 6 9 Fe NS 
[14] 48/F Myelodysplasia, 14 18 Fe Cunmng- 
splenectomy hamella 
[15] 42/M Dialysis 2 4 AI NS 
55/M Dialysis, 2 17 AI Rhizopus 
glucocorticoids 
49/F Dialysis 2-4 16 AI NS 
[16] 68/M Myelofibrosis 10.5 20 Fe Rhizopus 
Current 56/F Myelodysplasia 1-1.5 7 Fe Rhizopus 
case 
Skin, muscle, AraB/lived 
nodes 
Heart, lung, None/died 
brain 
Heart, lung, None/died 
brain 




Brain, heart, None/died 
lung 

















Heart, lung, None/died 
spleen, brain, 
thyroid 
Lung, brain, None/died 
skin 
Lung, liver, None/died 
spleen, heart 
Lung, skin, AmB/died 
brain 
Brain, lung AmB/died 
NS = not stated; Fe = iron overload: AI = aluminum overload: AmB = amphotericin B. 
tologic disorders requiring frequent transfusions [3- 
5,14,16]. Four patients, two with renal failure and two 
with hematologic disorders, had undergone splenecto- 
my previously [5,7,10,14]. Only one patient each had 
diabetes mellitus [4], corticosteroid therapy [15], or 
chemotherapy [5]. 
The indications for deferoxamine therapy were iron 
overload (nine patients) [3-5,8,11,13,14,16,current 
case], aluminum overload (14 patients) [6,8-11,15], 
and both iron and aluminum excess (three patients) 
[7,10,12]. All patients with aluminum excess were un- 
dergoing hemodialysis. The mean duration of deferox- 
amine therapy was 9.3 months, with a range from 19 
days to 20 months. The dose of deferoxamine ranged 
from 1 to 14 g per week. 
The clinical course noted in the patients in this se- 
ries did not differ from that noted in patients with 
other risk factors for mucormycosis. Fourteen patients 
(54%) had d i s semina ted  infect ion [3,5-8,10- 
12,15,16,current case]; pulmonary and brain involve- 
ment was most prominent in these patients. Seven 
p a t i e n t s  (27%) had r h i n o c e r e b r a l  disease 
[4,9,10,11,13], two had pulmonary infection [10,14], 
and one each had only cerebral, small bowel, or skin 
involvement, although it is likely that the latter pa- 
tient had disseminated infection [8,10,11]. Presenta- 
tion was acute in all but one patient, who presented 
with subacute infection of lymph nodes and subcuta- 
neous tissue [5]. 
The clinical course was commented upon in 19 cases 
(four with rhinocerebrai infection, 12 with disseminat- 
ed infection, and three with localized disease). In pa- 
tients with rhinocerebral infection, the mean duration 
of illness until death was only five days, and in those 
with disseminated infection, only six days. Rhinocere- 
bral infection presented as facial pain or rhinorrhea; 
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blindness occurred in three of four patients, and all 
four had increasing confusion and coma prior to death. 
Disseminated infection presented as necrotic cutane- 
ous lesions in two patients [12,16] and as pneumonitis 
(cough, fever, and p-lmonary infiltrates) in seven pa- 
tients [3,6,7,15,current case]. 
Only nine patients received any treatment that 
might have been helpful against mucormycosis. Three 
patients received amphotericin B alone: our patient, 
Sanes' [16] patient, who received only one day of am- 
photericin B therapy prior to death, and Sand's [51 
patient, who had subacute infection and was cured 
with 2 g of amphotericin B. Two patients had surgery 
alone--one had debridement of infected sinuses, 
which did not establish a diagnosis prior to death [13], 
and one had localized intestinal mucormycosis that 
was cured by surgical extirpation of the involved small 
bowel [8]. Four patients underwent surgical debride- 
ment of infected tissue and received treatment with 
amphotericin B [4,10,14]. In three instances, less than 
a week of therapy with amphotericin B was given prior 
to death. 
In 19 of 26 cases (73%), the diagnosis was not made 
until necropsy. Twenty-three of the 26 patients (88%) 
died of mucormycosis. Three patients survived with 
the following: localized disease of the bowel cured by 
surgical extirpation [8], a subacute course involving 
skin, subcutaneous tissue, and nodes, which respond- 
ed to amphotericin B therapy [5], and rhinocerebral 
infection treated with both surgical debridement and 
1.5 g of amphotericin B [10]. 
Necropsy reports uniformly described tissue inva- 
sion with broad non-septate hyphae. Invasion through 
blood vessel walls with multiple infarcts and multiple 
abscesses was a common finding. 
C O M M E N T S  
Mucormycosis is an opportunistic mycotic infection 
caused by organisms belonging to the order Mucorales 
and the class Zygomycetes. The organisms most com- 
monly implicated in clinical disease belong to the gen- 
era Mucor, Rhizopus, Absidia, and Cunninghamella 
[18]. Although wound infections with these organisms 
may occur in healthy individuals [19], invasive infec- 
tion almost always occurs in patients with underlying 
diseases, especially acute leukemias and poorly con- 
trolled diabetes meMtus [1,2]. Rhinocerebral and pul- 
monary forms of the disease are the most common 
presentations of invasive infection, but widespread 
dissemination may also occur [1,2]. 
Neutrophils and monocytes/macrophages are es- 
sential host defenses against the zygomycetes [20-23]. 
Patients with acute leukemia are at risk for developing 
mucormycosis primarily because of neutropenla [24]. 
However, patients with diabetes have normal numbers 
of neutrophils and generally normal phagocytic func- 
tion [25]. Thus, another factor predisposing the dia- 
betic patient to mucormycosis must be sought, and 
that factor may be ketoacidosis. Clinically, mucormy- 
cosis rarely occurs in diabetic patients unless they are 
experiencing ketoacidosis [20]. It has been shown in 
humans that ketoacidosis decreases neutrophil che- 
motaxis [26] and that in experimental alloxan-induced 
diabetes, ketoacidosis, and not hyperglycemia, is asso- 
ciated with invasive mucormycosis [27]. Not only is 
chemotaxis sluggish in ketoacidosis, but recent data 
show that serum inhibitory activity, which is normally 
present against the zygomycetes, is abolished in the 
course of ketoacidosis [28]. Thus, ketoacidotic serum 
will allow the growth of Rhizopus, but normal serum 
will not, unless the pH is lowered [28]. 
It is possible that acidosis is the essential factor 
leading to mucormycosis in patients undergoing dialy- 
sis. However, this seems unlikely since most patients 
have well-compensated acid-base balance, acidosis 
has not been noted specifically in those dialysis pa- 
tients reported with mucormycosis, and furthermore, 
this factor would not explain the recent dramatic in- 
crease in mucormycosis seen in patients undergoing 
dialysis. 
The increasing incidence of mucormycosis among 
patients undergoing dialysis and patients with chronic 
hematologic diseases can best be explained by the fact 
that all of these patients have been receiving the che- 
lating agent, deferoxamine, which may alter the bal- 
ance between iron metabolism of the host and iron 
requirements of the fungus. Many microorganisms re- 
quire iron to grow, and conditions of iron excess have 
been known to predispose to infection with certain 
bacteria [29,30]. In fact, recent reports have empha- 
sized that transfusion-related iron overload in pa- 
tients undergoing dialysis predisposes these patients 
to bacteremia with Yersinia and Listeria [31,32]. 
It is ironic that treatment with an agent that binds 
iron, such as deferoxamine, should be associated with 
an increased risk of infection with an iron-requiring 
organism such as Rhizopus. One would think that a 
chelator should decrease the risk of infection, and, in 
fact, that suggestion has been made [28]. The paradox 
of increased infection during chelation therapy can be 
explained by elucidation of how pathogenic microor- 
ganisms acquire iron from their host. 
In human plasma or on mucosal surfaces, the 
amount of free iron available for microbial growth is 
very low; almost all of the iron is bound to proteins, 
such as transferrin and lactoferrin, or is locked in tis- 
sue stores. Microorganisms have evolved complex 
mechanisms to compete for iron in the host, usually by 
secreting siderophores, which trap iron and deliver it 
to the microorganism, thus enhancing growth. One of 
these siderophores is desferrioxamine B mesylate (de- 
feroxamine) produced by Streptomyces pilosus. Thus, 
deferoxamine therapy provides benefit not only to hu- 
mans receiving it for iron excess, but also to certain 
microorganisms, which do not produce their own si- 
derophores but have the ability to utilize siderophores 
from other organisms [33]. The use of deferoxamine by 
bacteria to capture iron and increase virulence has 
been noted for both Yersinia enterocolitica and Vibrio 
vulnificus [34,35]. Clinically, yersinia bacteremia has 
been noted in patients undergoing dialysis who have 
received deferoxamine, but it is unclear whether the 
excess iron, use of the chelator, or both factors in- 
creased the risk for this infection [32,36,37]. 
It is likely that the zygomyeetes Rhizopus and Cun- 
ninghamella were able to utilize iron mobilized by de- 
feroxamine to proliferate and cause invasive infection. 
These zygomycetes have been shown to produce only 
minimal amounts of siderophores and then only at 
room temperature after weeks in culture [38,39]. The 
fact that many of these patients were treated for alu- 
minum excess and did not have iron overload impli- 
cates deferoxamine even more strongly. 
The dismal rate of premortem diagnosis in the pa- 
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tients reviewed contrasts sharply with the improved 
rate of diagnosis noted in recent years by Parfrey [2] 
and by Marchevsky et al [1]. This lack of early diagno- 
sis in the patients presented in this review probably 
reflects the fact that the association of mucormycosis 
with either aluminum or iron overload treated with 
deferoxamine has only very recently been noted. Cer- 
tainly, it is common knowledge that sinusitis, propto- 
sis, or palatal lesions in a patient with poorly con- 
trolled diabetes mellitus or a hematologic malignancy 
should immediately suggest rhinocerebral mucormy- 
cosis. Similarly, a new infarct-like pulmonary infil- 
trate or necrotic skin lesions in such a patient also 
suggest mucormycosis. It is clear from the 26 patients 
reported in the last seven years that the aforemen- 
tioned constellation of symptoms and signs in a pa- 
tient receiving deferoxamine for iron or aluminum ex- 
cess should also immediately raise the possibility of 
mucormycosis. 
The diagnosis of mucormycosis is best made by bi- 
opsy and histopathologic examination of involved tis- 
sues. Microscopy will reveal broad, irregularly shaped, 
non-septate hyphae with right-angle branching; the 
fungi are often seen invading through tissue planes 
and blood vessels. Cultures are necessary to identify 
the fungal species and to perform antifungal suscepti- 
bility studies. 
Since the mid-1970s, the prognosis of mucormycosis 
has improved markedly [1,2]. Therapy is based on ear- 
ly surgical debridement, amphotericin B administra- 
tion, and stabilization of any underlying disease pro- 
cess [2,20]. If surgical debridement or correction of the 
underlying disease process cannot be accomplished, 
the response to amphotericin B alone is poor. The 
Mucorales are modestly susceptible to amphotericin 
B, although in many instances it appears that in vitro 
susceptibility testing has not correlated well with the 
response of the patient to treatment with amphoteri- 
cin B [20]. Newer antifungal agents, such as imidazoles 
and triazoles, appear to have no role in the treatment 
of mucormycosis [40]. A patient with mucormycosis 
related to deferoxamine therapy should be able to be 
effectively treated, since the underlying risk factor can 
be corrected. However, the diagnosis must be made 
quickly for therapy to be effective. 
The implications of the association between defer- 
oxamine therapy and mucormycosis are evident. The 
indications for deferoxamine therapy should be care- 
fully weighed against the potential risk of mucormyco- 
sis. If deferoxamine is chosen, high clinical suspicion 
should be maintained for mucormycosis, especially if 
the patient presents with the aforementioned signs 
and symptoms. Immediate biopsy examination of in- 
volved tissue is essential for diagnosis, and cessation of 
deferoxamine, as well as aggressive surgical and anti- 
fungal therapy, is mandatory for survival. 
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